Sampling Human, an early stage, life science technology company that has developed a diagnostic platform that harnesses genetically engineered cells to analyze other cells in their environment, has raised $2 million led by the venture capital firm i&i Biotech Fund (i&i Bio). Longevitytech.fund and Formic Ventures also participated in the recent financing.

Sampling Human, Inc. is a synthetic biology diagnostics company developing novel methods for the early detection of disease. The company has developed simple and easy to perform diagnostic reagent kits for the liquid biopsy of healthy and diseased cells and a proprietary method of harnessing living cells to analyze other cells. The Company engineers and manufactures accessible tools that elevate sensitivity and increase speed of assay well beyond performance limits of complex instruments such as flow cytometry.